Navigation Links
Spherix Reports 3rd Quarter Earnings
Date:11/16/2007

BELTSVILLE, Md., Nov. 16 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX) has reported a loss from continuing operations of $3.1 million ($0.22 per share) and $7.1 million ($0.50 per share) for the three- and nine- months ended September 30, 2007, respectively. These losses exceeded the losses for the corresponding periods of 2006 due to increased expenditures related to the Company's Phase 3 clinical trial of Naturlose as a treatment for type 2 diabetes. The Company anticipates the trial to continue through mid-2009. Income from discontinued operations was $8.4 million ($0.59 per share) in the third quarter of 2007, and $8.3 million ($0.59 per share) for the nine months ended September 30, 2007, reflecting the sale of the InfoSpherix subsidiary (see Spherix press release dated August 16, 2007). The Company's total net income was $5.3 million (37 cents per share) and $1.3 million (9 cents per shared), respectively for the three- and nine-months ended September 30, 2007.

Claire L. Kruger, CEO, said, "The sale of InfoSpherix has provided the Company with significant funding that will help us to pursue the Company's strategic interests."

Three months ended Nine months ended

September 30, September 30,

2007 2006 2007 2006

Revenue from continuing

operations $ 59,000 $ - $ 63,000 $ 3,000

Loss from continuing

operations $(3,122,000) $(981,000) $(7,063,000)$(2,350,000)

Income from discontinued

operations $ 8,416,000 $ 971,000 $ 8,321,000 $ 2,046,000

Net income (loss) $ 5,294,000 $ (10,000 $ 1,258,000 $ (304,000)

Net income (loss) per

share

Continuing operations $ (0.22) $ (0.07 $ (0.50)$ (0.17)

Discontinued

operations $ 0.59 $ 0.07 $ 0.59 $ 0.15

Net income (loss) per

share $ 0.37 $ - $ 0.09 $ (0.02)

Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission, including the filing on Form 8-K made on October 10, 2007.

Under its motto, "A World of Solutions," Spherix's mission is to create value and increase shareholder wealth through innovations that benefit our clients and the human condition. Spherix offers innovations in information technology, knowledge management, and biotechnology.

Spherix's internet address is http://www.spherix.com.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... August 15, 2017 , ... Kenall, a leader in sealed ... stay tightly sealed and perform efficiently for years. The downlights are ideal for ... aren't enough, such as: hospitals; behavioral health facilities; cleanrooms; containment areas; food and ...
(Date:8/15/2017)... Yorba Linda, Ca (PRWEB) , ... August 15, ... ... world coffee production and is threatened by various biotic and abiotic factors. During ... the complex evolutionary history of coffee, as well as gain a better understanding ...
(Date:8/14/2017)... , ... August 14, 2017 , ... ... and performing antibodies. Key researchers in the antibody community have recently come together ... consistency for antibodies in the laboratory. , The team at ...
(Date:8/14/2017)... (PRWEB) , ... August 14, 2017 , ... The ... Trials event, which will take place on September 6, 2017 at the Marriott ... MD , Head of Experimental Medicine, Informatics, and Regulatory Strategy, Pfizer Innovative Research Lab, ...
Breaking Biology Technology:
(Date:5/6/2017)... SINGAPORE , May 5, 2017 ... has just announced a new breakthrough in biometric ... that exploits quantum mechanical properties to perform ... new smart semiconductor material created by Ram Group ... across finance, entertainment, transportation, supply chains and security. ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at http://www.nxt-id.com  under "SEC ... . 2016 Year Highlights: Acquisition ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
Breaking Biology News(10 mins):